1 0 1 0 1 O
week 2 6 2 6 O
washout 7 14 7 14 O
for 15 18 15 18 O
anakinra 19 27 19 27 B-treatment

2 0 1 28 29 B-lower_bound
week 2 6 30 34 I-lower_bound
washout 7 14 35 42 O
for 15 18 43 46 O
etanercept 19 29 47 57 B-treatment

3 0 1 58 59 B-upper_bound
month 2 7 60 65 I-upper_bound
washout 8 15 66 73 O
for 16 19 74 77 O
leflunomide 20 31 78 89 B-treatment
, 31 32 89 90 O
IVIg 33 37 91 95 B-treatment
or 38 40 96 98 O
cyclophosphamide 41 57 99 115 B-treatment

4 0 1 116 117 O
week 2 6 118 122 O
washout 7 14 123 130 O
for 15 18 131 134 O
methotrexate 19 31 135 147 B-treatment

6 0 1 148 149 B-upper_bound
month 2 7 150 155 I-upper_bound
washout 8 15 156 163 O
for 16 19 164 167 O
rituximab 20 29 168 177 B-treatment

8 0 1 178 179 O
week 2 6 180 184 O
washout 7 14 185 192 O
for 15 18 193 196 O
any 19 22 197 200 O
other 23 28 201 206 O
IS 29 31 207 209 B-treatment
agent 32 37 210 215 I-treatment
( 38 39 216 217 O
e.g. 39 43 217 221 O
azathioprine 44 56 222 234 B-treatment
, 56 57 234 235 O
cyclosporine 58 70 236 248 B-treatment
, 70 71 248 249 O
tacrolimus 72 82 250 260 B-treatment
, 82 83 260 261 O
mycophenolate 84 97 262 275 B-treatment
mofetil 98 105 276 283 I-treatment
) 105 106 283 284 O

8 0 1 285 286 O
week 2 6 287 291 O
washout 7 14 292 299 O
for 15 18 300 303 O
infliximab 19 29 304 314 B-treatment
or 30 32 315 317 O
adalimumab 33 43 318 328 B-treatment

Absolute 0 8 329 337 B-clinical_variable
Lymphocyte 9 19 338 348 I-clinical_variable
Count 20 25 349 354 I-clinical_variable
< 26 27 355 356 O
0.5 28 31 357 360 B-upper_bound
x 32 33 361 362 I-upper_bound
109 34 37 363 366 I-upper_bound
/ 37 38 366 367 I-upper_bound
L 38 39 367 368 I-upper_bound
( 40 41 369 370 I-upper_bound
500 41 44 370 373 I-upper_bound
/ 44 45 373 374 I-upper_bound
mm3 45 48 374 377 I-upper_bound
) 48 49 377 378 I-upper_bound

Absolute 0 8 379 387 B-clinical_variable
Neutrophil 9 19 388 398 I-clinical_variable
Count 20 25 399 404 I-clinical_variable
< 26 27 405 406 O
2.0 28 31 407 410 B-upper_bound
x 32 33 411 412 I-upper_bound
109 34 37 413 416 I-upper_bound
/ 37 38 416 417 I-upper_bound
L 38 39 417 418 I-upper_bound
( 40 41 419 420 I-upper_bound
2000 41 45 420 424 I-upper_bound
/ 45 46 424 425 I-upper_bound
mm3 46 49 425 428 I-upper_bound
) 49 50 428 429 I-upper_bound

Active 0 6 430 436 B-chronic_disease
TB 7 9 437 439 I-chronic_disease
requiring 10 19 440 449 O
treatment 20 29 450 459 B-treatment
within 30 36 460 466 O
the 37 40 467 470 O
previous 41 49 471 479 B-upper_bound
3 50 51 480 481 I-upper_bound
years 52 57 482 487 I-upper_bound

Any 0 3 488 491 O
major 4 9 492 497 O
episode 10 17 498 505 O
of 18 20 506 508 O
infection 21 30 509 518 B-chronic_disease
requiring 31 40 519 528 O
hospitalization 41 56 529 544 O
or 57 59 545 547 O
treatment 60 69 548 557 B-treatment
with 70 74 558 562 I-treatment
IV 75 77 563 565 I-treatment
antibiotics 78 89 566 577 I-treatment
within 90 96 578 584 O
4 97 98 585 586 B-upper_bound
weeks 99 104 587 592 I-upper_bound
of 105 107 593 595 O
screening 108 117 596 605 O
or 118 120 606 608 O
oral 121 125 609 613 B-treatment
antibiotics 126 137 614 625 I-treatment
within 138 144 626 632 O
2 145 146 633 634 B-upper_bound
weeks 147 152 635 640 I-upper_bound
prior 153 158 641 646 I-upper_bound
to 159 161 647 649 O
screening 162 171 650 659 O

Body 0 4 660 664 B-clinical_variable
weight 5 11 665 671 I-clinical_variable
of 12 14 672 674 O
> 15 16 675 676 O
150 17 20 677 680 B-lower_bound
kg 21 23 681 683 I-lower_bound

Concomitant 0 11 684 695 B-treatment
IS 12 14 696 698 I-treatment
medications 15 26 699 710 I-treatment
permitted 27 36 711 720 O
include 37 44 721 728 O
methotrexate 45 57 729 741 B-treatment
, 57 58 741 742 O
azathioprine 59 71 743 755 B-treatment
, 71 72 755 756 O
cyclosporine 73 85 757 769 B-treatment
, 85 86 769 770 O
mycophenolate 87 100 771 784 B-treatment
mofetil 101 108 785 792 I-treatment
, 108 109 792 793 O
and 110 113 794 797 O
tacrolimus 114 124 798 808 B-treatment

Definite 0 8 809 817 O
or 9 11 818 820 O
probable 12 20 821 829 O
PM 21 23 830 832 O
or 24 26 833 835 O
DM 27 29 836 838 O
by 30 32 839 841 O
the 33 36 842 845 O
criteria 37 45 846 854 O
of 46 48 855 857 O
Bohan 49 54 858 863 O
and 55 58 864 867 O
Peter 59 64 868 873 O
( 65 66 874 875 O
as 66 68 875 877 O
modified 69 77 878 886 O
by 78 80 887 889 O
IMACS 81 86 890 895 O
) 86 87 895 896 O
in 88 90 897 899 O
adults 91 97 900 906 O
over 98 102 907 911 O
the 103 106 912 915 O
age 107 110 916 919 B-age
of 111 113 920 922 O
18 114 116 923 925 B-lower_bound

Elevation 0 9 926 935 O
of 10 12 936 938 O
at 13 15 939 941 O
least 16 21 942 947 O
one 22 25 948 951 B-lower_bound
of 26 28 952 954 O
the 29 32 955 958 O
muscle 33 39 959 965 B-clinical_variable
enzymes 40 47 966 973 I-clinical_variable
( 48 49 974 975 O
CK 49 51 975 977 B-clinical_variable
, 51 52 977 978 O
AST 53 56 979 982 B-clinical_variable
, 56 57 982 983 O
ALT 58 61 984 987 B-clinical_variable
, 61 62 987 988 O
aldolase 63 71 989 997 B-clinical_variable
, 71 72 997 998 O
LDH 73 76 999 1002 B-clinical_variable
) 76 77 1002 1003 O
at 78 80 1004 1006 O
a 81 82 1007 1008 O
minimum 83 90 1009 1016 O
level 91 96 1017 1022 O
of 97 99 1023 1025 O
1.3x 100 104 1026 1030 B-lower_bound
the 105 108 1031 1034 I-lower_bound
ULN 109 112 1035 1038 I-lower_bound

Evidence 0 8 1039 1047 O
of 9 11 1048 1050 O
active 12 18 1051 1057 O
malignant 19 28 1058 1067 B-cancer
disease 29 36 1068 1075 I-cancer
, 36 37 1075 1076 O
malignancies 38 50 1077 1089 B-cancer
diagnosed 51 60 1090 1099 O
within 61 67 1100 1106 O
the 68 71 1107 1110 O
previous 72 80 1111 1119 B-upper_bound
5 81 82 1120 1121 I-upper_bound
years 83 88 1122 1127 I-upper_bound
( 89 90 1128 1129 O
including 90 99 1129 1138 O
hematological 100 113 1139 1152 B-cancer
malignancies 114 126 1153 1165 I-cancer
and 127 130 1166 1169 O
solid 131 136 1170 1175 B-cancer
tumors 137 143 1176 1182 I-cancer
, 143 144 1182 1183 O
except 145 151 1184 1190 O
basal 152 157 1191 1196 B-cancer
and 158 161 1197 1200 O
squamous 162 170 1201 1209 B-cancer
cell 171 175 1210 1214 I-cancer
carcinoma 176 185 1215 1224 I-cancer
of 186 188 1225 1227 O
the 189 192 1228 1231 O
skin 193 197 1232 1236 O
or 198 200 1237 1239 O
carcinoma 201 210 1240 1249 B-cancer
in 211 213 1250 1252 I-cancer
situ 214 218 1253 1257 I-cancer
of 219 221 1258 1260 I-cancer
the 222 225 1261 1264 I-cancer
cervix 226 232 1265 1271 I-cancer
uteri 233 238 1272 1277 O
that 239 243 1278 1282 O
has 244 247 1283 1286 O
been 248 252 1287 1291 O
excised 253 260 1292 1299 O
and 261 264 1300 1303 O
cured 265 270 1304 1309 O
) 270 271 1309 1310 O
, 271 272 1310 1311 O
or 273 275 1312 1314 O
breast 276 282 1315 1321 O
cancer 283 289 1322 1328 O
diagnosed 290 299 1329 1338 O
within 300 306 1339 1345 O
the 307 310 1346 1349 O
previous 311 319 1350 1358 B-upper_bound
10 320 322 1359 1361 I-upper_bound
years 323 328 1362 1367 I-upper_bound
unless 329 335 1368 1374 O
related 336 343 1375 1382 O
to 344 346 1383 1385 O
primary 347 354 1386 1393 O
disease 355 362 1394 1401 O
under 363 368 1402 1407 O
investigation 369 382 1408 1421 O

Evidence 0 8 1422 1430 O
of 9 11 1431 1433 O
serious 12 19 1434 1441 O
uncontrolled 20 32 1442 1454 O
concomitant 33 44 1455 1466 O
cardiovascular 45 59 1467 1481 B-chronic_disease
, 59 60 1481 1482 O
nervous 61 68 1483 1490 B-chronic_disease
system 69 75 1491 1497 I-chronic_disease
, 75 76 1497 1498 O
pulmonary 77 86 1499 1508 B-chronic_disease
( 87 88 1509 1510 O
including 88 97 1510 1519 O
obstructive 98 109 1520 1531 B-chronic_disease
pulmonary 110 119 1532 1541 I-chronic_disease
disease 120 127 1542 1549 I-chronic_disease
) 127 128 1549 1550 O
, 128 129 1550 1551 O
renal 130 135 1552 1557 B-chronic_disease
, 135 136 1557 1558 O
hepatic 137 144 1559 1566 B-chronic_disease
, 144 145 1566 1567 O
endocrine 146 155 1568 1577 B-chronic_disease
( 156 157 1578 1579 O
include 157 164 1579 1586 O
uncontrolled 165 177 1587 1599 O
diabetes 178 186 1600 1608 B-chronic_disease
mellitus 187 195 1609 1617 I-chronic_disease
) 195 196 1617 1618 O
or 197 199 1619 1621 O
gastrointestinal 200 216 1622 1638 B-chronic_disease
disease 217 224 1639 1646 I-chronic_disease
( 225 226 1647 1648 O
including 226 235 1648 1657 O
complicated 236 247 1658 1669 O
diverticulitis 248 262 1670 1684 B-chronic_disease
, 262 263 1684 1685 O
ulcerative 264 274 1686 1696 B-chronic_disease
colitis 275 282 1697 1704 I-chronic_disease
, 282 283 1704 1705 O
or 284 286 1706 1708 O
Crohn 287 292 1709 1714 B-chronic_disease
's 292 294 1714 1716 I-chronic_disease
disease 295 302 1717 1724 I-chronic_disease
. 302 303 1724 1725 O
) 303 304 1725 1726 O

Global 0 6 1727 1733 B-clinical_variable
extramuscular 7 20 1734 1747 I-clinical_variable
disease 21 28 1748 1755 I-clinical_variable
activity 29 37 1756 1764 I-clinical_variable
score 38 43 1765 1770 I-clinical_variable
with 44 48 1771 1775 O
a 49 50 1776 1777 O
minimum 51 58 1778 1785 O
value 59 64 1786 1791 O
of 65 67 1792 1794 O
1.0 68 71 1795 1798 B-lower_bound
cm 71 73 1798 1800 I-lower_bound
on 74 76 1801 1803 O
a 77 78 1804 1805 O
10 79 81 1806 1808 B-upper_bound
cm 81 83 1808 1810 I-upper_bound
VAS 84 87 1811 1814 B-clinical_variable
scale 88 93 1815 1820 O
on 94 96 1821 1823 O
the 97 100 1824 1827 O
Myositis 101 109 1828 1836 O
Disease 110 117 1837 1844 O
Activity 118 126 1845 1853 O
Assessment 127 137 1854 1864 O
Tool 138 142 1865 1869 O
( 143 144 1870 1871 O
MDAAT 144 149 1871 1876 O
) 149 150 1876 1877 O

HAQ 0 3 1878 1881 B-clinical_variable
disability 4 14 1882 1892 I-clinical_variable
index 15 20 1893 1898 I-clinical_variable
with 21 25 1899 1903 O
a 26 27 1904 1905 O
minimum 28 35 1906 1913 O
value 36 41 1914 1919 O
of 42 44 1920 1922 O
0.25 45 49 1923 1927 B-lower_bound

History 0 7 1928 1935 O
of 8 10 1936 1938 O
alcohol 11 18 1939 1946 O
, 18 19 1946 1947 O
drug 20 24 1948 1952 O
or 25 27 1953 1955 O
chemical 28 36 1956 1964 O
abuse 37 42 1965 1970 O
within 43 49 1971 1977 O
1 50 51 1978 1979 B-upper_bound
year 52 56 1980 1984 I-upper_bound
prior 57 62 1985 1990 I-upper_bound
to 63 65 1991 1993 O
screening 66 75 1994 2003 O
or 76 78 2004 2006 O
any 79 82 2007 2010 O
medical 83 90 2011 2018 O
condition 91 100 2019 2028 O
or 101 103 2029 2031 O
physical 104 112 2032 2040 O
or 113 115 2041 2043 O
psychological 116 129 2044 2057 O
state 130 135 2058 2063 O
that 136 140 2064 2068 O
the 141 144 2069 2072 O
PI 145 147 2073 2075 O
feels 148 153 2076 2081 O
would 154 159 2082 2087 O
not 160 163 2088 2091 O
allow 164 169 2092 2097 O
the 170 173 2098 2101 O
subject 174 181 2102 2109 O
to 182 184 2110 2112 O
safely 185 191 2113 2119 O
complete 192 200 2120 2128 O
the 201 204 2129 2132 O
study 205 210 2133 2138 O

History 0 7 2139 2146 O
of 8 10 2147 2149 O
severe 11 17 2150 2156 O
allergic 18 26 2157 2165 O
or 27 29 2166 2168 O
anaphylactic 30 42 2169 2181 O
reactions 43 52 2182 2191 O
to 53 55 2192 2194 O
human 56 61 2195 2200 B-allergy_name
, 61 62 2200 2201 O
humanized 63 72 2202 2211 B-allergy_name
or 73 75 2212 2214 O
murine 76 82 2215 2221 B-allergy_name
monoclonal 83 93 2222 2232 I-allergy_name
antibodies 94 104 2233 2243 I-allergy_name

IVIg 0 4 2244 2248 B-treatment
will 5 9 2249 2253 O
also 10 14 2254 2258 O
be 15 17 2259 2261 O
allowed 18 25 2262 2269 O
as 26 28 2270 2272 O
an 29 31 2273 2275 O
immunomodulatory 32 48 2276 2292 B-treatment
agent 49 54 2293 2298 I-treatment

If 0 2 2299 2301 O
an 3 5 2302 2304 O
IS 6 8 2305 2307 O
agent 9 14 2308 2313 O
is 15 17 2314 2316 O
continued 18 27 2317 2326 O
, 27 28 2326 2327 O
the 29 32 2328 2331 O
dose 33 37 2332 2336 O
must 38 42 2337 2341 O
remain 43 49 2342 2348 O
stable 50 56 2349 2355 O
for 57 60 2356 2359 O
4 61 62 2360 2361 B-upper_bound
weeks 63 68 2362 2367 I-upper_bound
prior 69 74 2368 2373 I-upper_bound
to 75 77 2374 2376 O
enrollment 78 88 2377 2387 O
and 89 92 2388 2391 O
at 93 95 2392 2394 O
least 96 101 2395 2400 O
until 102 107 2401 2406 O
the 108 111 2407 2410 O
DOI 112 115 2411 2414 O
is 116 118 2415 2417 O
met 119 122 2418 2421 O
or 123 125 2422 2424 O
if 126 128 2425 2427 O
safety 129 135 2428 2434 O
/ 135 136 2434 2435 O
toxicity 136 144 2435 2443 O
issues 145 151 2444 2450 O
supervene 152 161 2451 2460 O

If 0 2 2461 2463 O
on 3 5 2464 2466 O
prednisone 6 16 2467 2477 B-treatment
, 16 17 2477 2478 O
the 18 21 2479 2482 O
dose 22 26 2483 2487 O
must 27 31 2488 2492 O
be 32 34 2493 2495 O
stable 35 41 2496 2502 O
for 42 45 2503 2506 O
4 46 47 2507 2508 B-upper_bound
weeks 48 53 2509 2514 I-upper_bound
prior 54 59 2515 2520 I-upper_bound
to 60 62 2521 2523 O
the 63 66 2524 2527 O
screening 67 76 2528 2537 O
visit 77 82 2538 2543 O

Immunization 0 12 2544 2556 B-treatment
with 13 17 2557 2561 I-treatment
a 18 19 2562 2563 I-treatment
live 20 24 2564 2568 I-treatment
/ 24 25 2568 2569 I-treatment
attenuated 25 35 2569 2579 I-treatment
vaccine 36 43 2580 2587 I-treatment
within 44 50 2588 2594 O
4 51 52 2595 2596 B-upper_bound
weeks 53 58 2597 2602 I-upper_bound
prior 59 64 2603 2608 I-upper_bound
to 65 67 2609 2611 O
baseline 68 76 2612 2620 O

Initiation 0 10 2621 2631 O
of 11 13 2632 2634 O
an 14 16 2635 2637 O
exercise 17 25 2638 2646 O
program 26 33 2647 2654 O
for 34 37 2655 2658 O
muscle 38 44 2659 2665 O
strengthening 45 58 2666 2679 O
within 59 65 2680 2686 O
4 66 67 2687 2688 B-upper_bound
weeks 68 73 2689 2694 I-upper_bound
of 74 76 2695 2697 O
the 77 80 2698 2701 O
screening 81 90 2702 2711 O
visit 91 96 2712 2717 O
or 97 99 2718 2720 O
initiation 100 110 2721 2731 O
of 111 113 2732 2734 O
a 114 115 2735 2736 O
muscle 116 122 2737 2743 O
strengthening 123 136 2744 2757 O
exercise 137 145 2758 2766 O
program 146 153 2767 2774 O
during 154 160 2775 2781 O
the 161 164 2782 2785 O
study 165 170 2786 2791 O

Investigators 0 13 2792 2805 O
will 14 18 2806 2810 O
be 19 21 2811 2813 O
certain 22 29 2814 2821 O
to 30 32 2822 2824 O
assess 33 39 2825 2831 O
and 40 43 2832 2835 O
classify 44 52 2836 2844 O
adverse 53 60 2845 2852 O
events 61 67 2853 2859 O
as 68 70 2860 2862 O
being 71 76 2863 2868 O
secondary 77 86 2869 2878 O
to 87 89 2879 2881 O
either 90 96 2882 2888 O
study 97 102 2889 2894 O
drug 103 107 2895 2899 O
as 108 110 2900 2902 O
well 111 115 2903 2907 O
as 116 118 2908 2910 O
any 119 122 2911 2914 O
concomitant 123 134 2915 2926 O
immunosuppressive 135 152 2927 2944 B-treatment
agent(s 153 160 2945 2952 I-treatment
) 160 161 2952 2953 I-treatment

Known 0 5 2954 2959 O
active 6 12 2960 2966 O
current 13 20 2967 2974 O
or 21 23 2975 2977 O
history 24 31 2978 2985 O
of 32 34 2986 2988 O
recurrent 35 44 2989 2998 B-chronic_disease
bacterial 45 54 2999 3008 I-chronic_disease
, 54 55 3008 3009 O
viral 56 61 3010 3015 B-chronic_disease
, 61 62 3015 3016 O
fungal 63 69 3017 3023 B-chronic_disease
, 69 70 3023 3024 O
mycobacterial 71 84 3025 3038 B-chronic_disease
or 85 87 3039 3041 O
other 88 93 3042 3047 O
infections 94 104 3048 3058 B-chronic_disease
( 105 106 3059 3060 O
including 106 115 3060 3069 O
but 116 119 3070 3073 O
not 120 123 3074 3077 O
limited 124 131 3078 3085 O
to 132 134 3086 3088 O
tuberculosis 135 147 3089 3101 B-chronic_disease
and 148 151 3102 3105 O
atypical 152 160 3106 3114 B-chronic_disease
mycobacterial 161 174 3115 3128 I-chronic_disease
disease 175 182 3129 3136 I-chronic_disease
, 182 183 3136 3137 O
Hepatitis 184 193 3138 3147 B-chronic_disease
B 194 195 3148 3149 I-chronic_disease
and 196 199 3150 3153 I-chronic_disease
C 200 201 3154 3155 I-chronic_disease
, 201 202 3155 3156 O
and 203 206 3157 3160 O
herpes 207 213 3161 3167 B-chronic_disease
zoster 214 220 3168 3174 I-chronic_disease

MD 0 2 3175 3177 B-clinical_variable
global 3 9 3178 3184 I-clinical_variable
VAS 10 13 3185 3188 I-clinical_variable
with 14 18 3189 3193 O
a 19 20 3194 3195 O
minimum 21 28 3196 3203 O
value 29 34 3204 3209 O
of 35 37 3210 3212 O
2.0 38 41 3213 3216 B-lower_bound
cm 41 43 3216 3218 I-lower_bound
on 44 46 3219 3221 O
a 47 48 3222 3223 O
10 49 51 3224 3226 B-upper_bound
cm 51 53 3226 3228 I-upper_bound
scale 54 59 3229 3234 O

Major 0 5 3235 3240 B-treatment
surgery 6 13 3241 3248 I-treatment
( 14 15 3249 3250 O
including 15 24 3250 3259 O
joint 25 30 3260 3265 B-treatment
surgery 31 38 3266 3273 I-treatment
) 38 39 3273 3274 O
within 40 46 3275 3281 O
8 47 48 3282 3283 B-upper_bound
weeks 49 54 3284 3289 I-upper_bound
prior 55 60 3290 3295 I-upper_bound
to 61 63 3296 3298 O
screening 64 73 3299 3308 O
or 74 76 3309 3311 O
planned 77 84 3312 3319 O
major 85 90 3320 3325 B-treatment
surgery 91 98 3326 3333 I-treatment
within 99 105 3334 3340 O
6 106 107 3341 3342 B-upper_bound
months 108 114 3343 3349 I-upper_bound
following 115 124 3350 3359 O
randomization 125 138 3360 3373 O

Men 0 3 3374 3377 B-gender
and 4 7 3378 3381 O
women 8 13 3382 3387 B-gender
of 14 16 3388 3390 O
reproductive 17 29 3391 3403 O
potential 30 39 3404 3413 O
must 40 44 3414 3418 O
agree 45 50 3419 3424 B-contraception_consent
to 51 53 3425 3427 I-contraception_consent
use 54 57 3428 3431 I-contraception_consent
an 58 60 3432 3434 I-contraception_consent
acceptable 61 71 3435 3445 I-contraception_consent
method 72 78 3446 3452 I-contraception_consent
of 79 81 3453 3455 I-contraception_consent
birth 82 87 3456 3461 I-contraception_consent
control 88 95 3462 3469 I-contraception_consent
during 96 102 3470 3476 O
treatment 103 112 3477 3486 B-treatment
and 113 116 3487 3490 O
for 117 120 3491 3494 O
twelve 121 127 3495 3501 B-upper_bound
months 128 134 3502 3508 I-upper_bound
after 135 140 3509 3514 O
completion 141 151 3515 3525 O
of 152 154 3526 3528 O
treatment 155 164 3529 3538 O

No 0 2 3539 3541 O
concomitant 3 14 3542 3553 O
biologic 15 23 3554 3562 B-treatment
agents 24 30 3563 3569 I-treatment
are 31 34 3570 3573 O
allowed 35 42 3574 3581 O
( 43 44 3582 3583 O
rituximab 44 53 3583 3592 B-treatment
, 53 54 3592 3593 O
anti 55 59 3594 3598 B-treatment
- 59 60 3598 3599 I-treatment
TNFs 60 64 3599 3603 I-treatment
, 64 65 3603 3604 O
abatacept 66 75 3605 3614 B-treatment
) 75 76 3614 3615 O
as 77 79 3616 3618 O
well 80 84 3619 3623 O
as 85 87 3624 3626 O
cyclophosphamide 88 104 3627 3643 B-treatment
or 105 107 3644 3646 O
tofacitinib 108 119 3647 3658 B-treatment
as 120 122 3659 3661 O
concomitant 123 134 3662 3673 B-treatment
immunosuppressive 135 152 3674 3691 I-treatment
agents 153 159 3692 3698 I-treatment

Patient 0 7 3699 3706 O
global 8 14 3707 3713 O
VAS 15 18 3714 3717 B-clinical_variable
with 19 23 3718 3722 O
a 24 25 3723 3724 O
minimum 26 33 3725 3732 O
value 34 39 3733 3738 O
of 40 42 3739 3741 O
2.0 43 46 3742 3745 B-lower_bound
cm 46 48 3745 3747 I-lower_bound
on 49 51 3748 3750 O
a 52 53 3751 3752 O
10 54 56 3753 3755 B-upper_bound
cm 56 58 3755 3757 I-upper_bound
scale 59 64 3758 3763 O

Patients 0 8 3764 3772 O
treated 9 16 3773 3780 O
for 17 20 3781 3784 O
tuberculosis 21 33 3785 3797 B-chronic_disease
with 34 38 3798 3802 O
no 39 41 3803 3805 O
recurrence 42 52 3806 3816 O
in 53 55 3817 3819 O
3 56 57 3820 3821 B-upper_bound
years 58 63 3822 3827 I-upper_bound
are 64 67 3828 3831 O
permitted 68 77 3832 3841 O

Patients 0 8 3842 3850 O
with 9 13 3851 3855 O
lack 14 18 3856 3860 O
of 19 21 3861 3863 O
peripheral 22 32 3864 3874 B-treatment
venous 33 39 3875 3881 I-treatment
access 40 46 3882 3888 I-treatment

Patients 0 8 3889 3897 O
with 9 13 3898 3902 O
reproductive 14 26 3903 3915 O
potential 27 36 3916 3925 O
not 37 40 3926 3929 B-contraception_consent
willing 41 48 3930 3937 I-contraception_consent
to 49 51 3938 3940 I-contraception_consent
use 52 55 3941 3944 I-contraception_consent
an 56 58 3945 3947 I-contraception_consent
effective 59 68 3948 3957 I-contraception_consent
method 69 75 3958 3964 I-contraception_consent
of 76 78 3965 3967 I-contraception_consent
contraception 79 92 3968 3981 I-contraception_consent

Platelet 0 8 3982 3990 B-clinical_variable
count 9 14 3991 3996 I-clinical_variable
< 15 16 3997 3998 O
( 17 18 3999 4000 B-upper_bound
100,000 18 25 4000 4007 I-upper_bound
/ 25 26 4007 4008 I-upper_bound
mm3 26 29 4008 4011 I-upper_bound
) 29 30 4011 4012 I-upper_bound

Positive 0 8 4013 4021 O
hepatitis 9 18 4022 4031 B-chronic_disease
BsAg 19 23 4032 4036 I-chronic_disease
or 24 26 4037 4039 O
hepatitis 27 36 4040 4049 B-chronic_disease
C 37 38 4050 4051 I-chronic_disease
antibody 39 47 4052 4060 O

Prednisone 0 10 4061 4071 B-treatment
Tapering 11 19 4072 4080 O
: 19 20 4080 4081 O
Prednisone 21 31 4082 4092 O
should 32 38 4093 4099 O
be 39 41 4100 4102 O
held 42 46 4103 4107 O
constant 47 55 4108 4116 O
without 56 63 4117 4124 O
tapering 64 72 4125 4133 O
or 73 75 4134 4136 O
escalation 76 86 4137 4147 O
( 87 88 4148 4149 O
unless 88 94 4149 4155 O
there 95 100 4156 4161 O
is 101 103 4162 4164 O
a 104 105 4165 4166 O
serious 106 113 4167 4174 O
adverse 114 121 4175 4182 O
event 122 127 4183 4188 O
or 128 130 4189 4191 O
disease 131 138 4192 4199 O
flare 139 144 4200 4205 O
) 144 145 4205 4206 O
until 146 151 4207 4212 O
the 152 155 4213 4216 O
subject 156 163 4217 4224 O
has 164 167 4225 4228 O
achieved 168 176 4229 4237 O
the 177 180 4238 4241 O
DOI 181 184 4242 4245 O

Prednisone 0 10 4246 4256 B-treatment
at 11 13 4257 4259 O
Entry 14 19 4260 4265 O
: 19 20 4265 4266 O
It 21 23 4267 4269 O
is 24 26 4270 4272 O
also 27 31 4273 4277 O
recommended 32 43 4278 4289 O
that 44 48 4290 4294 O
patients 49 57 4295 4303 O
be 58 60 4304 4306 O
on 61 63 4307 4309 O
less 64 68 4310 4314 O
than 69 73 4315 4319 O
1mg 74 77 4320 4323 B-upper_bound
/ 77 78 4323 4324 I-upper_bound
kg 78 80 4324 4326 I-upper_bound
/ 80 81 4326 4327 I-upper_bound
day 81 84 4327 4330 I-upper_bound
of 85 87 4331 4333 O
prednisone 88 98 4334 4344 B-treatment
at 99 101 4345 4347 O
study 102 107 4348 4353 O
entry 108 113 4354 4359 O

Pregnant 0 8 4360 4368 B-pregnancy
women 9 14 4369 4374 B-gender

Previous 0 8 4375 4383 B-treatment
treatment 9 18 4384 4393 I-treatment
with 19 23 4394 4398 O
TCZ 24 27 4399 4402 B-treatment

Previous 0 8 4403 4411 B-treatment
treatment 9 18 4412 4421 I-treatment
with 19 23 4422 4426 I-treatment
the 24 27 4427 4430 I-treatment
following 28 37 4431 4440 I-treatment
cell 38 42 4441 4445 I-treatment
- 42 43 4445 4446 I-treatment
depleting 43 52 4446 4455 I-treatment
therapies 53 62 4456 4465 I-treatment
, 62 63 4465 4466 O
including 64 73 4467 4476 O
investigational 74 89 4477 4492 B-treatment
agents 90 96 4493 4499 I-treatment
or 97 99 4500 4502 O
approved 100 108 4503 4511 O
therapies 109 118 4512 4521 O
: 118 119 4521 4522 O
CAMPATH 120 127 4523 4530 B-treatment
, 127 128 4530 4531 O
anti 129 133 4532 4536 B-treatment
- 133 134 4536 4537 I-treatment
CD4 134 137 4537 4540 I-treatment
, 137 138 4540 4541 O
anti 139 143 4542 4546 B-treatment
- 143 144 4546 4547 I-treatment
CD5 144 147 4547 4550 I-treatment
, 147 148 4550 4551 O
and 149 152 4552 4555 O
anti¬CD3 153 161 4556 4564 B-treatment

Primary 0 7 4565 4572 O
or 8 10 4573 4575 O
secondary 11 20 4576 4585 O
immunodeficiency 21 37 4586 4602 B-chronic_disease
( 38 39 4603 4604 O
history 39 46 4604 4611 O
of 47 49 4612 4614 O
or 50 52 4615 4617 O
currently 53 62 4618 4627 O
active 63 69 4628 4634 O
) 69 70 4634 4635 O
unless 71 77 4636 4642 O
related 78 85 4643 4650 O
to 86 88 4651 4653 O
primary 89 96 4654 4661 O
disease 97 104 4662 4669 O
under 105 110 4670 4675 O
investigation 111 124 4676 4689 O

Refractory 0 10 4690 4700 O
myositis 11 19 4701 4709 B-chronic_disease
patients 20 28 4710 4718 O
are 29 32 4719 4722 O
defined 33 40 4723 4730 O
( 41 42 4731 4732 O
see 42 45 4732 4735 O
Section 46 53 4736 4743 O
3.1.1 54 59 4744 4749 O
) 59 60 4749 4750 O
as 61 63 4751 4753 O
having 64 70 4754 4760 O
failed 71 77 4761 4767 O
( 78 79 4768 4769 O
or 79 81 4769 4771 O
considered 82 92 4772 4782 O
intolerant 93 103 4783 4793 O
to 104 106 4794 4796 O
) 106 107 4796 4797 O
an 108 110 4798 4800 O
adequate 111 119 4801 4809 O
course 120 126 4810 4816 O
of 127 129 4817 4819 O
glucocorticoids 130 145 4820 4835 B-treatment
or 146 148 4836 4838 O
having 149 155 4839 4845 O
failed 156 162 4846 4852 O
glucocorticoids 163 178 4853 4868 O
and 179 182 4869 4872 O
at 183 185 4873 4875 O
least 186 191 4876 4881 O
one 192 195 4882 4885 B-lower_bound
other 196 201 4886 4891 O
immunosuppressive 202 219 4892 4909 B-treatment
( 220 221 4910 4911 I-treatment
IS 221 223 4911 4913 I-treatment
) 223 224 4913 4914 I-treatment
or 225 227 4915 4917 O
immunomodulatory 228 244 4918 4934 B-treatment
agent 245 250 4935 4940 I-treatment
( 251 252 4941 4942 O
e.g. 252 256 4942 4946 O
methotrexate 257 269 4947 4959 B-treatment
, 269 270 4959 4960 O
azathioprine 271 283 4961 4973 B-treatment
, 283 284 4973 4974 O
cyclosporine 285 297 4975 4987 B-treatment
, 297 298 4987 4988 O
tacrolimus 299 309 4989 4999 B-treatment
, 309 310 4999 5000 O
mycophenolate 311 324 5001 5014 B-treatment
mofetil 325 332 5015 5022 I-treatment
, 332 333 5022 5023 O
cyclophosphamide 334 350 5024 5040 B-treatment
, 350 351 5040 5041 O
IVIg 352 356 5042 5046 B-treatment
, 356 357 5046 5047 O
anti 358 362 5048 5052 B-treatment
- 362 363 5052 5053 I-treatment
TNF 363 366 5053 5056 I-treatment
agents 367 373 5057 5063 I-treatment
, 373 374 5063 5064 O
and 375 378 5065 5068 O
rituximab 379 388 5069 5078 B-treatment
) 388 389 5078 5079 O

Serum 0 5 5080 5085 B-clinical_variable
creatinine 6 16 5086 5096 I-clinical_variable
> 17 18 5097 5098 O
1.6 19 22 5099 5102 B-lower_bound
mg 23 25 5103 5105 I-lower_bound
/ 25 26 5105 5106 I-lower_bound
dL 26 28 5106 5108 I-lower_bound
in 29 31 5109 5111 O
female 32 38 5112 5118 B-gender
patients 39 47 5119 5127 I-gender
and 48 51 5128 5131 O
> 52 53 5132 5133 O
1.9 54 57 5134 5137 B-lower_bound
mg 58 60 5138 5140 I-lower_bound
/ 60 61 5140 5141 I-lower_bound
dL 61 63 5141 5143 I-lower_bound
in 64 66 5144 5146 O
male 67 71 5147 5151 O
patients 72 80 5152 5160 O

Severe 0 6 5161 5167 O
muscle 7 13 5168 5174 B-clinical_variable
damage 14 20 5175 5181 I-clinical_variable
defined 21 28 5182 5189 O
as 29 31 5190 5192 O
a 32 33 5193 5194 O
global 34 40 5195 5201 O
muscle 41 47 5202 5208 O
damage 48 54 5209 5215 O
score 55 60 5216 5221 O
> 61 62 5222 5223 O
5 62 63 5223 5224 B-lower_bound
on 64 66 5225 5227 O
a 67 68 5228 5229 O
10 69 71 5230 5232 O
cm 71 73 5232 5234 O
VAS 74 77 5235 5238 B-clinical_variable
scale 78 83 5239 5244 I-clinical_variable
on 84 86 5245 5247 O
the 87 90 5248 5251 O
Muscle 91 97 5252 5258 B-clinical_variable
Damage 98 104 5259 5265 I-clinical_variable
Index 105 110 5266 5271 I-clinical_variable
( 111 112 5272 5273 I-clinical_variable
MDI 112 115 5273 5276 I-clinical_variable
) 115 116 5276 5277 I-clinical_variable

Subjects 0 8 5278 5286 O
must 9 13 5287 5291 O
either 14 20 5292 5298 O
have 21 25 5299 5303 O
the 26 29 5304 5307 O
classic 30 37 5308 5315 O
rash(es 38 45 5316 5323 O
) 45 46 5323 5324 O
of 47 49 5325 5327 O
DM 50 52 5328 5330 B-chronic_disease
( 53 54 5331 5332 O
heliotrope 54 64 5332 5342 B-chronic_disease
, 64 65 5342 5343 O
Gottron 66 73 5344 5351 B-chronic_disease
sign 74 78 5352 5356 I-chronic_disease
or 79 81 5357 5359 O
Gottron 82 89 5360 5367 B-chronic_disease
papules 90 97 5368 5375 I-chronic_disease
) 97 98 5375 5376 O
, 98 99 5376 5377 O
possess 100 107 5378 5385 O
one 108 111 5386 5389 O
of 112 114 5390 5392 O
the 115 118 5393 5396 O
myositis 119 127 5397 5405 B-treatment
- 127 128 5405 5406 I-treatment
associated 128 138 5406 5416 I-treatment
autoantibodies 139 153 5417 5431 I-treatment
( 154 155 5432 5433 O
e.g. 155 159 5433 5437 O
anti 160 164 5438 5442 B-treatment
- 164 165 5442 5443 I-treatment
synthetase 165 175 5443 5453 I-treatment
, 175 176 5453 5454 O
anti 177 181 5455 5459 B-treatment
- 181 182 5459 5460 I-treatment
SRP 182 185 5460 5463 I-treatment
, 185 186 5463 5464 O
anti 187 191 5465 5469 B-treatment
- 191 192 5469 5470 I-treatment
Mi-2 192 196 5470 5474 I-treatment
, 196 197 5474 5475 O
anti 198 202 5476 5480 B-treatment
- 202 203 5480 5481 I-treatment
PM 203 205 5481 5483 I-treatment
- 205 206 5483 5484 I-treatment
Scl 206 209 5484 5487 I-treatment
, 209 210 5487 5488 O
anti 211 215 5489 5493 B-treatment
TIF1 216 220 5494 5498 I-treatment
- 220 221 5498 5499 I-treatment
γ 221 222 5499 5500 I-treatment
etc 223 226 5501 5504 O
. 226 227 5504 5505 O
) 227 228 5505 5506 O
, 228 229 5506 5507 O
or 230 232 5508 5510 O
have 233 237 5511 5515 O
the 238 241 5516 5519 O
diagnosis 242 251 5520 5529 O
of 252 254 5530 5532 O
PM 255 257 5533 5535 O
agreed 258 264 5536 5542 O
upon 265 269 5543 5547 O
by 270 272 5548 5550 O
a 273 274 5551 5552 O
3 275 276 5553 5554 O
- 276 277 5554 5555 O
member 277 283 5555 5561 O
Adjudication 284 296 5562 5574 O
Committee 297 306 5575 5584 O
consisting 307 317 5585 5595 O
of 318 320 5596 5598 O
a 321 322 5599 5600 O
rheumatologist 323 337 5601 5615 O
, 337 338 5615 5616 O
neurologist 339 350 5617 5628 O
and 351 354 5629 5632 O
neuromuscular 355 368 5633 5646 O
pathologist 369 380 5647 5658 O

Subjects 0 8 5659 5667 O
under 9 14 5668 5673 O
the 15 18 5674 5677 O
age 19 22 5678 5681 B-age
of 23 25 5682 5684 O
18 26 28 5685 5687 B-upper_bound

Subjects 0 8 5688 5696 O
with 9 13 5697 5701 O
an 14 16 5702 5704 O
MMT-8 17 22 5705 5710 B-clinical_variable
score 23 28 5711 5716 I-clinical_variable
> 29 30 5717 5718 O
66 31 33 5719 5721 B-lower_bound

Subjects 0 8 5722 5730 O
with 9 13 5731 5735 O
an 14 16 5736 5738 O
MMT-8 17 22 5739 5744 B-clinical_variable
score 23 28 5745 5750 I-clinical_variable
≤ 29 30 5751 5752 O
66 31 33 5753 5755 B-upper_bound

Then 0 4 5756 5760 O
, 4 5 5760 5761 O
tapering 6 14 5762 5770 O
of 15 17 5771 5773 O
prednisone 18 28 5774 5784 B-treatment
may 29 32 5785 5788 O
commence 33 41 5789 5797 O
using 42 47 5798 5803 O
a 48 49 5804 5805 O
schedule 50 58 5806 5814 O
approximating 59 72 5815 5828 O
a 73 74 5829 5830 O
20 75 77 5831 5833 B-lower_bound
- 77 78 5833 5834 O
25 78 80 5834 5836 B-upper_bound
% 80 81 5836 5837 I-upper_bound
taper 82 87 5838 5843 O
of 88 90 5844 5846 O
the 91 94 5847 5850 O
existing 95 103 5851 5859 O
dose 104 108 5860 5864 O
every 109 114 5865 5870 O
4 115 116 5871 5872 B-upper_bound
weeks 117 122 5873 5878 I-upper_bound
based 123 128 5879 5884 O
on 129 131 5885 5887 O
the 132 135 5888 5891 O
clinical 136 144 5892 5900 O
judgment 145 153 5901 5909 O
of 154 156 5910 5912 O
the 157 160 5913 5916 O
clinical 161 169 5917 5925 O
site 170 174 5926 5930 O
investigator 175 187 5931 5943 O

Treatment 0 9 5944 5953 B-treatment
with 10 14 5954 5958 O
any 15 18 5959 5962 O
investigational 19 34 5963 5978 B-treatment
agent 35 40 5979 5984 I-treatment
within 41 47 5985 5991 O
4 48 49 5992 5993 B-upper_bound
weeks 50 55 5994 5999 I-upper_bound
( 56 57 6000 6001 O
or 57 59 6001 6003 O
5 60 61 6004 6005 B-upper_bound
half 62 66 6006 6010 I-upper_bound
- 66 67 6010 6011 I-upper_bound
lives 67 72 6011 6016 I-upper_bound
of 73 75 6017 6019 O
the 76 79 6020 6023 O
investigational 80 95 6024 6039 B-treatment
drug 96 100 6040 6044 I-treatment
, 100 101 6044 6045 O
whichever 102 111 6046 6055 O
is 112 114 6056 6058 O
longer 115 121 6059 6065 O
) 121 122 6065 6066 O
of 123 125 6067 6069 O
screening 126 135 6070 6079 O

We 0 2 6080 6082 O
will 3 7 6083 6087 O
also 8 12 6088 6092 O
allow 13 18 6093 6098 O
enrollment 19 29 6099 6109 O
of 30 32 6110 6112 O
JDM 33 36 6113 6116 B-chronic_disease
patients 37 45 6117 6125 O
( 46 47 6126 6127 O
considered 47 57 6127 6137 O
to 58 60 6138 6140 O
have 61 65 6141 6145 O
DM 66 68 6146 6148 O
) 68 69 6148 6149 O
over 70 74 6150 6154 O
the 75 78 6155 6158 O
age 79 82 6159 6162 B-age
of 83 85 6163 6165 O
18 86 88 6166 6168 B-lower_bound
who 89 92 6169 6172 O
otherwise 93 102 6173 6182 O
meet 103 107 6183 6187 O
the 108 111 6188 6191 O
inclusion 112 121 6192 6201 O
criteria 122 130 6202 6210 O
stipulated 131 141 6211 6221 O
below 142 147 6222 6227 O

fungal 0 6 6228 6234 B-chronic_disease
infections 7 17 6235 6245 I-chronic_disease
of 18 20 6246 6248 O
nail 21 25 6249 6253 O
beds 26 30 6254 6258 O

hemoglobin 0 10 6259 6269 B-clinical_variable
< 11 12 6270 6271 O
8.5 13 16 6272 6275 B-upper_bound
g 17 18 6276 6277 I-upper_bound
/ 18 19 6277 6278 I-upper_bound
dl 19 21 6278 6280 I-upper_bound
and 22 25 6281 6284 O
WBC 26 29 6285 6288 B-clinical_variable
count 30 35 6289 6294 I-clinical_variable
< 36 37 6295 6296 O
3000 38 42 6297 6301 B-upper_bound
/ 42 43 6301 6302 I-upper_bound
mm3 43 46 6302 6305 I-upper_bound

there 0 5 6306 6311 O
are 6 9 6312 6315 O
complications 10 23 6316 6329 O
or 24 26 6330 6332 O
circumstances 27 40 6333 6346 O
that 41 45 6347 6351 O
, 45 46 6351 6352 O
in 47 49 6353 6355 O
the 50 53 6356 6359 O
clinical 54 62 6360 6368 O
site 63 67 6369 6373 O
investigator 68 80 6374 6386 O
's 80 82 6386 6388 O
opinion 83 90 6389 6396 O
, 90 91 6396 6397 O
necessitate 92 103 6398 6409 O
the 104 107 6410 6413 O
tapering 108 116 6414 6422 O
of 117 119 6423 6425 O
corticosteroids 120 135 6426 6441 B-treatment

